Your browser is no longer supported. Please, upgrade your browser.
Settings
FPRX [NASD]
Five Prime Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.29 Insider Own0.80% Shs Outstand36.83M Perf Week0.29%
Market Cap1.77B Forward P/E- EPS next Y-1.81 Insider Trans-94.96% Shs Float26.05M Perf Month0.58%
Income-84.30M PEG- EPS next Q-0.47 Inst Own86.40% Short Float11.41% Perf Quarter154.01%
Sales13.20M P/S134.07 EPS this Y41.60% Inst Trans49.29% Short Ratio1.37 Perf Half Y540.81%
Book/sh7.20 P/B5.28 EPS next Y8.30% ROA-38.30% Target Price37.17 Perf Year1252.31%
Cash/sh6.17 P/C6.16 EPS next 5Y- ROE-54.90% 52W Range2.61 - 38.90 Perf YTD123.40%
Dividend- P/FCF- EPS past 5Y-17.60% ROI-32.50% 52W High-2.31% Beta4.57
Dividend %- Quick Ratio13.20 Sales past 5Y-48.90% Gross Margin- 52W Low1355.94% ATR0.21
Employees51 Current Ratio13.20 Sales Q/Q312.50% Oper. Margin- RSI (14)73.44 Volatility0.14% 0.37%
OptionableNo Debt/Eq0.00 EPS Q/Q-156.80% Profit Margin- Rel Volume0.44 Prev Close38.00
ShortableYes LT Debt/Eq0.00 EarningsMar 10 AMC Payout- Avg Volume2.17M Price38.00
Recom2.60 SMA200.44% SMA5021.51% SMA200150.56% Volume0 Change0.00%
Nov-11-20Upgrade Wells Fargo Equal Weight → Overweight $34
Nov-11-20Upgrade ROTH Capital Neutral → Buy $9 → $30
Nov-11-20Upgrade JP Morgan Underweight → Neutral $14
Sep-22-20Upgrade Guggenheim Neutral → Buy $11
Jun-22-20Upgrade Wedbush Neutral → Outperform $5 → $9
Feb-28-20Downgrade JP Morgan Neutral → Underweight
Feb-18-20Downgrade Wedbush Outperform → Neutral
Nov-20-19Resumed Guggenheim Neutral
Oct-01-19Downgrade Guggenheim Buy → Neutral
Jun-03-19Downgrade Wells Fargo Outperform → Market Perform
May-29-19Initiated ROTH Capital Neutral $10
Apr-12-19Resumed Guggenheim Buy $24
Sep-13-18Resumed Leerink Partners Outperform $24
Jun-28-18Initiated Raymond James Mkt Perform
Jun-15-18Initiated JP Morgan Neutral $19
May-18-18Initiated Wedbush Neutral
Nov-06-17Reiterated RBC Capital Mkts Outperform $41 → $50
Sep-15-17Initiated RBC Capital Mkts Outperform $41
Mar-02-17Initiated Instinet Buy $94
Oct-25-16Initiated Citigroup Buy
Apr-16-21 08:25AM  
Apr-05-21 03:29PM  
Apr-04-21 08:00AM  
Apr-01-21 05:10PM  
Mar-30-21 08:17AM  
Mar-25-21 03:15PM  
08:05AM  
Mar-23-21 10:45AM  
Mar-20-21 08:35PM  
03:26PM  
Mar-19-21 07:49PM  
02:29PM  
Mar-18-21 05:13PM  
02:16PM  
Mar-16-21 10:34AM  
Mar-14-21 11:28AM  
Mar-11-21 10:25PM  
06:55PM  
Mar-10-21 03:14PM  
01:30PM  
Mar-09-21 05:00PM  
01:16PM  
10:22AM  
Mar-08-21 01:41PM  
08:59AM  
Mar-05-21 10:02PM  
07:03PM  
01:05PM  
10:56AM  
10:05AM  
07:31AM  
04:10AM  
Mar-04-21 06:27PM  
05:48PM  
04:19PM  
03:34PM  
02:04PM  
01:43PM  
01:06PM  
01:00PM  
12:02PM  
11:45AM  
11:35AM  
10:46AM  
08:30AM  
07:27AM  
06:54AM  
Mar-03-21 12:30PM  
Mar-02-21 04:05PM  
Feb-26-21 05:00PM  
Feb-22-21 06:00PM  
Feb-05-21 09:25AM  
Jan-15-21 06:55AM  
Dec-21-20 01:20AM  
Dec-17-20 11:18PM  
Dec-09-20 05:00PM  
Dec-08-20 10:00AM  
Dec-07-20 08:29AM  
Dec-05-20 04:00PM  
Nov-17-20 05:00PM  
10:00AM  
Nov-13-20 07:40AM  
Nov-12-20 10:00PM  
04:16PM  
08:34AM  
07:44AM  
Nov-11-20 05:45PM  
04:19PM  
04:01PM  
02:00PM  
01:24PM  
12:22PM  
11:11AM  
08:30AM  
07:38AM  
07:36AM  
Nov-10-20 07:00PM  
04:12PM  
Nov-06-20 06:47AM  
Nov-03-20 05:15PM  
04:21PM  
04:05PM  
02:45PM  
Nov-02-20 06:30PM  
Oct-28-20 12:32PM  
Oct-27-20 10:29PM  
Oct-13-20 02:47PM  
Oct-12-20 08:48AM  
Oct-09-20 09:50AM  
Sep-22-20 09:36AM  
Sep-09-20 06:30PM  
Aug-13-20 03:30PM  
Aug-10-20 12:56PM  
12:55PM  
Aug-06-20 08:30PM  
04:05PM  
Jul-30-20 12:33PM  
Jul-29-20 07:00PM  
06:30PM  
12:33PM  
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of immuno-oncology and targeted cancer therapies. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b to treat patients with gastric or gastroesophageal junction and GEJ cancer; FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28 that is in Phase Ia/1b clinical trial for patients with solid tumors; and BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase I/II clinical trial in combination with Opdivo in patients with advanced malignant tumors. Its preclinical programs include FPA157, an anti-CCR8 antibody that is engineered to eliminate CCR8-expressing CD4+ regulatory T cells within solid tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, and BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sarena Francis WillardChief Strategy OfficerDec 11Option Exercise0.0022,0000138,010Dec 15 12:19 PM
Smith David VExecutive Vice President & CFODec 11Option Exercise0.0022,000089,561Dec 15 12:09 PM
Collins Helen LouiseEVP and Chief Medical OfficerDec 11Option Exercise0.0022,000097,117Dec 15 12:00 PM
RINGO WILLIAM RDirectorNov 11Option Exercise2.4178,959190,36962,959Nov 13 12:17 PM
Sarena Francis WillardChief Strategy OfficerNov 11Option Exercise0.0022,0000127,011Nov 13 12:38 PM
Smith David VExecutive Vice President & CFONov 11Option Exercise0.0022,000085,389Nov 13 12:29 PM
Collins Helen LouiseEVP and Chief Medical OfficerNov 11Option Exercise0.0022,000086,156Nov 13 12:25 PM
BVF PARTNERS L P/ILSee Explanaton of ResponsesNov 11Sale20.197,393,340149,247,13781,263Nov 13 05:29 PM
RINGO WILLIAM RDirectorNov 11Sale22.5078,9591,776,57810,000Nov 13 12:17 PM
BVF PARTNERS L P/IL10% OwnerNov 06Buy4.9830,000149,5204,611,909Nov 06 06:30 PM
BVF PARTNERS L P/IL10% OwnerNov 04Buy4.88416,5622,034,5724,594,679Nov 06 06:30 PM
BVF PARTNERS L P/IL10% OwnerOct 06Buy5.04345,2411,738,2884,336,875Oct 08 05:27 PM
BVF PARTNERS L P/IL10% OwnerSep 22Buy3.8032122541,116Sep 24 07:49 PM
BVF PARTNERS L P/IL10% OwnerMay 14Buy4.10293,5871,203,7074,179,093May 18 08:02 PM